Clinical trials
Amyloidosis clinical trials
Below are recruiting amyloidosis clinical trials, each written for real people, not researchers. We’re tracking 150 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05758493RecruitingPhase 2
Iodine-124 scan study for systemic amyloidosis
This Phase 2 study tests an iodine-based scan medicine to help learn how systemic amyloidosis affects the body and organs. It may help doctors better characterize the disease using specific imaging tests.
Portland, OregonAges 40–90 - NCT05145816RecruitingPhase 1/Phase 2
Belantamab for AL amyloidosis after prior treatments
This study tests belantamab mafodotin, a medicine designed to target amyloid-producing abnormal cells, in people with relapsed or refractory AL (light-chain) amyloidosis. It’s aimed at improving blood and organ-related signs of the disease after earlier treatments have stopped working.
Nashville, TennesseeAges 18 years+ - NCT05101304Recruiting
European registry for people with amyloidosis
This study collects health information from people who may have amyloidosis or who already have a confirmed diagnosis. It aims to better understand amyloidosis in real-world care across European centers, which can help future patients and treatments.
CréteilAges Any age - NCT06129656Recruiting
Cardiac Amyloidosis Registry at Leipzig Hospital
This study is a registry that collects information from people with cardiac amyloidosis. It helps doctors learn more about the condition and how to better treat it.
Leipzig, SaxonyAges Any age - NCT06376214Recruiting
Daratumumab for newly diagnosed light chain amyloidosis
This trial tests the drug daratumumab in people newly diagnosed with light chain amyloidosis that affects the heart, kidney, or liver. The goal is to see if daratumumab can help control the disease. Eligibility depends on your disease stage and overall health.
Nanjing, JiangsuAges 18–75 - NCT07771621Enrolling by invitationPhase 1
PET scan for detecting heart amyloidosis
This study tests a new PET imaging agent that may help doctors see amyloid buildup in the heart more clearly. It may help people with heart amyloidosis or those suspected of having it.
St Louis, MissouriAges 18 years+ - NCT07752732Recruiting
Heart scans for amyloidosis in people with severe aortic valve stenosis
This study looks at how often cardiac amyloidosis occurs in people with severe aortic valve stenosis. It uses different heart scans to find out more. If you have both conditions, this research may help doctors understand your situation better.
TübingenAges 18 years+ - NCT07648303Recruiting
Study of blood clots in hearts with amyloidosis
This study looks at how often blood clots form in the hearts of people with cardiac amyloidosis (a disease where abnormal proteins build up in heart tissue). Understanding clot risk may help doctors better protect patients from stroke and other complications.
DijonAges 18 years+ - NCT07638683RecruitingPhase 2
Teclistamab and Daratumumab for New Multiple Myeloma With Amyloidosis
This trial tests a combination of two newer cancer-fighting drugs (teclistamab and daratumumab) to treat people who have just been diagnosed with multiple myeloma—a blood cancer—and also have light chain amyloidosis, a condition where abnormal proteins build up in organs. The goal is to see if this combination works better and is safe for newly diagnosed patients.
ShanghaiAges 18 years+ - NCT07644325Recruiting
Comparing Two Biopsy Methods for Carpal Tunnel Amyloidosis
This study compares two small tissue samples taken during carpal tunnel surgery to see which method best detects a protein disease (transthyretin amyloidosis) that can affect nerves and the heart. If you have carpal tunnel syndrome and are having surgery, this research may help doctors diagnose related heart or nerve problems earlier.
MontpellierAges 18 years+ - NCT07583823Recruiting
Higher-Rate Pacing for Heart Amyloid Disease
This study tests whether pacing your heart at a faster rate helps people with cardiac amyloidosis (a condition where abnormal protein builds up in the heart). If you have a pacemaker and cardiac amyloidosis, this research might help doctors understand the best pacing settings for you.
Minneapolis, MinnesotaAges 18 years+ - NCT07549841RecruitingPhase 2
Heart imaging study for transthyretin amyloidosis
This study tests a new type of heart imaging scan called [68Ga]Ga-FAPI-46 PET to help doctors see and track transthyretin cardiac amyloidosis (a disease where abnormal proteins damage the heart). The scan may help identify which patients are getting worse.
NantesAges 18 years+ - NCT06342466RecruitingPhase 2
Study of bortezomib, pomalidomide, and dexamethasone for AL amyloidosis
This trial tests a combination of three drugs—bortezomib, pomalidomide, and dexamethasone—to see how well they work for people with AL amyloidosis, a condition where abnormal proteins build up in organs. You may join if you are newly diagnosed or have had prior treatment and your organs are affected.
Beijing, Beijing MunicipalityAges 18–90 - NCT07494942Recruiting
Cardiac rehab for heart amyloidosis
This trial tests a 5-week cardiac rehabilitation program for people with cardiac amyloidosis (a condition where abnormal protein builds up in the heart). The program aims to improve heart function and quality of life.
MontpellierAges 18 years+ - NCT04535349Recruiting
Imaging heart uptake of bone tracer in ATTR amyloidosis
This study uses special imaging tracers to see how much they build up in the heart in people with cardiac transthyretin (ATTR) amyloidosis. It may help researchers better measure disease activity and understand who benefits from treatments like tafamidis.
CaenAges 18–100 - NCT07448779Recruiting
A study on N-glycosylation and its role in AL amyloidosis
This research study looks at how certain sugar molecules (N-glycosylation) on proteins may play a role in a disease called AL amyloidosis. Researchers will study blood samples from people with related plasma cell disorders to learn more about these sugars, which could help with diagnosis and treatment.
Pavia, PVAges 18–99 - NCT07448935Recruiting
Understanding a gene's role in AL amyloidosis and POEMS
This study looks at how a specific gene (IGLV1-44) affects two rare diseases: AL amyloidosis and POEMS syndrome. It involves a blood draw and possibly a bone marrow sample to learn more about how the gene works in these conditions.
PaviaAges 18–99 - NCT07435168Recruiting
Chest pain and hidden cardiac amyloidosis study
This study looks for signs of a condition called cardiac amyloidosis in people who have chest pain but no blocked heart arteries. It aims to find hidden cases that might be missed with standard tests.
CopenhagenAges 65 years+ - NCT06082050RecruitingEarly Phase 1
YOLT-201 for transthyretin heart disease
This trial tests a new intravenous medicine called YOLT-201 for people with a heart condition caused by buildup of a protein called transthyretin (ATTR-CM). The goal is to see if it can slow or improve the disease.
Hangzhou, ZhejiangAges 18–80 - NCT07388602RecruitingPhase 3
New drug combo for newly diagnosed AL amyloidosis
This trial tests a new drug (SCTC21C) combined with three standard chemotherapy medicines for people who have just been diagnosed with AL amyloidosis. The goal is to see if adding the new drug helps reduce the abnormal protein deposits better than the standard treatment alone.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06836011Recruiting
Heart valve leakage study in a type of amyloid heart disease
This study looks at how common and how serious heart valve leaks are in people with transthyretin amyloid cardiomyopathy (a condition where abnormal protein builds up in the heart). The goal is to better understand these leaks and how they affect long-term health.
Graz, StyriaAges 18 years+ - NCT07335887RecruitingPhase 2
Sonrotoclax and dexamethasone with or without daratumumab for AL amyloidosis with t(11;14)
This trial tests a new drug combination for people with a specific type of AL amyloidosis (light chain amyloidosis) that has a genetic marker called t(11;14). The treatment includes Sonrotoclax (a targeted therapy) plus steroids, and possibly another drug called daratumumab, to see if it can help control the disease.
BeijingAges 18 years+ - NCT02798705Recruiting
Testing heart tiny blood vessel function in amyloidosis
This study measures how well the heart’s tiny blood vessels work in people with cardiac amyloidosis, using special heart testing. It may help doctors understand the disease better and improve how patients are evaluated over time.
SeoulAges 18–85 - NCT05797857Recruiting
Exercise program for transthyretin heart amyloidosis
This trial studies whether a structured exercise training program is safe and helpful for people with transthyretin (ATTR) cardiac amyloidosis. It may help improve fitness and daily functioning, and it may also compare groups for specific eligibility needs.
Boston, MassachusettsAges 60–90
Hear when a new Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for amyloidosis?
- Yes. Clin2 currently lists 150 recruiting amyloidosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a amyloidosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a amyloidosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.